The Bookout Center will focus on enhancing the use of robotics and imaging in medicine. Photo via Houston Methodist

A groundbreaking new institution is coming to Houston Methodist.

The Bookout Center will build on the success of the Houston Methodist Institute for Technology, Innovation and Education (MITIE).

The new center will focus on enhancing the use of robotics and imaging in medicine. Virtual reality, robotics, AI, and other technologies will all play a part in the support that The Bookout Center will provide for health care professionals at all levels and specialties. High-resolution imaging and diagnostics will also be part of the forward-thinking research center.

The Bookout Center, which will be housed in the Houston Methodist Academic Institute, is the result of an undisclosed donation amount from Ann and John F. Bookout III. At the age of 100, John’s father, also named John Bookout, is an active Houston Methodist Board member and served as its chair from 1991 until 2007.

“We’re excited and humbled to have the support of the Bookout family,” Marc L. Boom, president and CEO of Houston Methodist, says in a press release. “The Bookouts believe in what our physicians, researchers and scientists do to bring life-changing treatments to our patients and community, and this gift will help us build on our legacy of leading medicine. We are so very grateful for this gift.”

A medical director for The Bookout Center has already been named. The role will be filled by Alan Lumsden, the Walter W. Fondren III Presidential Distinguished Chair in the Houston Methodist DeBakey Heart & Vascular Center and Chair of the Department of Cardiovascular Surgery. Dr. Lumsden will work alongside Dr. Stuart Corr, newly appointed director of Innovation Engineering for The Bookout Center, and associate professor of Bioengineering, to develop, implement, and lead the center’s activities.

"The Bookout Center will complement our existing programs with robust research, clinical trials and the expertise to develop further innovation in these fields,” Lumsden says. “We are grateful to the Bookouts for giving us the opportunity to lead the world in developing and refining these life-saving technologies, which will continue to improve outcomes and recovery times for patients.”

The new institute will be run by director Alan Lumsden, the Walter W. Fondren III Presidential Distinguished Chair in the Houston Methodist DeBakey Heart & Vascular Center and Chair of the Department of Cardiovascular Surgery. Photo via TMC.edu

Houston Methodist received its second largest gift in the hospital's 102-year history. Courtesy of Methodist Hospital/Facebook

Houston hospital receives anonymous $50M donation to support specialty treatments

big time gift

On the heels of kicking off construction for a $1.4 billion hospital tower at the Texas Medical Center, Houston Methodist has announced an anonymous $50 million gift.

The donation is the second largest received in the 102-year history of Houston Methodist.

Coupled with matching gifts and other sources of money, the gift’s overall impact will exceed $154 million, Houston Methodist says. Among the areas that will benefit from the funds are orthopedics, sports medicine, neuroprosthetics, gastrointestinal medicine, and immunology.

“Houston Methodist is honored to have the support of generous donors who entrust us to continue building on our legacy of leading medicine,” Dr. Marc Boom, president and CEO of Houston Methodist, says in a news release.

“This donor represents the giving spirit of the Houston community and believes in the unparalleled work our physicians, researchers, and staff do to bring lifesaving and life-changing treatments to our patients throughout the city and the country,” Boom adds. “We’re humbled to have this support and excited for what it will help us accomplish in the future.”

Highlights of the gift’s impact include:

  • Creation of an endowed position for the Houston Methodist Neuromodulation & Recovery Laboratory in collaboration with Rice University’s George R. Brown School of Engineering.
  • Support of the Center for Musculoskeletal Regeneration and Joint Preservation and Outcomes Laboratory.
  • Establishment of at least 20 endowments and support of special programs in areas such as imaging, nursing, ophthalmology, reconstructive surgery, surgery, and women’s health.

Earlier this month, Houston Methodist said it started construction on the 26-story Centennial Tower at the Texas Medical Center.

Set to open in 2027, the tower will include a larger emergency department and hundreds of patient beds, among other features. The new tower will replace Houston Methodist’s Houston Main building and West Pavilion.

Houston Methodist received millions in donations to support cancer patients. Courtesy of Methodist Hospital/Facebook

Houston hospital receives $37M in donations to continue its life-saving cancer care

guardian angels

A $25 million gift will support expansion of research conducted at the Houston Methodist Cancer Center and may help the center earn top-tier federal designation.

In honor of the $25 million donation from Dr. Mary Neal and husband Ron Neal, the cancer center is being renamed the Houston Methodist Dr. Mary and Ron Neal Cancer Center. The hospital system will raise an additional $12 million in matching funds, bringing the total to $37 million.

Dr. Marc Boom, president and CEO of Houston Methodist, says the Bellaire couple's gift "plays an important role in advancing our leading medicine mission and bringing potentially life-saving cancer treatments to more patients throughout Houston and the nation."

Mary Neal, previously in private practice as an obstetrician-gynecologist, is now a part-time volunteer physician at Houston Methodist's San Jose Clinic. Ron Neal is co-founder and co-owner of offshore development company Houston Energy. He also is CEO of Houston-based HEQ Deepwater, a more than $400 million venture formed earlier this year by Houston Energy and Houston-based private equity firm Quantum Energy Partners to buy deepwater assets in the Gulf of Mexico.

With the donation from Dr. Mary Neal and husband Ron Neal, the cancer center is being renamed the Houston Methodist Dr. Mary and Ron Neal Cancer Center. Photo courtesy of Houston Methodist

The Neals' donation will boost ongoing research led by Dr. Jenny Chang, director of the cancer center and Emily Herrmann Presidential Distinguished Chair in Cancer Research. Chang's research has advanced cancer therapy with breakthroughs such as targeted drugs for treatment of breast cancer.

Mary Neal says she and her husband believe their contribution "will further advance pivotal and innovative research beyond chemotherapy and radiation."

The gift also will fund and retain three endowed chairs and complementary funding for early stage research and therapies, support recruitment and fellowship training, and expand clinical trials at all of the community hospitals within Houston Methodist. Part of the gift is dedicated to cancer innovation efforts within the Center for Drug Repositioning and Development.

"Our vision for the Dr. Mary and Ron Neal Cancer Center is to grow our network of cancer physicians offering comprehensive care with the latest technologies and clinical trials so that patients across the region have the best access to cancer care," Chang says. "While the gift from the Neal family will have direct impact for patients at the community level in areas that are often deserts for cancer care, my hope is that it will also propel our ongoing research and work to the national level toward NCI designation."

Cancer centers designated by the National Cancer Institute (NCI) meet rigorous standards for research and clinical care. The Neals' gift is aimed at elevating research done at the cancer center and helping retain talent to accelerate Houston Methodist's pursuit of NCI designation.

Texas is home to four NCI-designated cancer centers:

  • Dan L Duncan Comprehensive Cancer Center at Houston's Baylor College of Medicine.
  • University of Texas MD Anderson Cancer Center, also in Houston.
  • Harold C. Simmons Comprehensive Cancer Center at the University of Texas Southwestern Medical Center in Dallas.
  • Mays Cancer Center at the University of Texas Health Science Center in San Antonio.

NCI designation represents "the highest federal rating a cancer center can achieve," according to the University of Chicago's NCI-designated cancer center. "It's the gold standard for cancer programs, and is bestowed upon the nation's top cancer centers in recognition of their innovative research and leading-edge treatments."

This designation can lead to benefits such as more research grants, quicker access to clinical trials for cancer treatments, and stepped-up recruitment of high-profile cancer researchers.

"At any given time, hundreds of research studies are under way at the cancer centers, ranging from basic laboratory research to clinical assessments of new treatments," the NCI says. "Many of these studies are collaborative and may involve several cancer centers, as well as other partners in industry and the community."

Houston Methodist is offering COVID-19 monoclonal antibody treatment thanks to a new partnership with Soleo Health. Photo via Getty Images

Houston hospital taps Texas company to offer in-home COVID-19 treatment

home care

Houston Methodist has tapped Frisco-based Soleo Health to provide in-home monoclonal antibody therapy for COVID-19 patients in the Houston area.

The Houston Methodist health care system has a partnership with the U.S. Department of Health and Human Services aimed at boosting access to COVID-19 monoclonal antibody treatment for underserved and disadvantaged patients in the Houston area.

Monoclonal antibodies are laboratory-made proteins that mimic the immune system's ability to fight off harmful pathogens such as viruses. If administered within 10 days of the onset of COVID-19 symptoms, the one-time therapy can neutralize the virus and prevent symptoms from worsening.

Soleo, a provider of specialized pharmacy services that has a location in Houston, says treating COVID-19 patients at home with monoclonal antibodies is expected to help reduce hospital admissions.

"By teaming up with Houston Methodist to help patients receive therapy and stay in their homes, we are helping reduce the chance of increased infections and the spread of COVID-19 in a hospital setting," Shahram Badrei of Houston, regional business leader at Soleo, says in a news release.

Houston Methodist reported in May that it had administered monoclonal antibodies to nearly 4,200 patients since the U.S. Food and Drug Administration (FDA) issued emergency use authorization for the treatment last November. The health care system said it was rolling out monoclonal antibody therapy at its more than 40 clinics in the Houston area. Houston Methodist ranks among the largest providers of monoclonal antibodies in the U.S.

Harris County, the state's most populous county, has recorded the most COVID-19 cases (539,000) and deaths (nearly 7,900) of any county in Texas.

"Houston Methodist continues to serve the Houston area and beyond in the fight against COVID-19 through patient care and its commitment to research that brings promising new therapies to fight the disease," Dr. Marc Boom, president and CEO of Houston Methodist, said in May.

Peter Pisters is one of the top 10 CEOs, according to Glassdoor. Photo courtesy of MD Anderson

3 Houston head honchos rank among America's top CEOs in new report

best of

Three Houston-area CEOs are doing a exemplary job of leading, says a new report.

Dr. Peter Pisters (MD Anderson Cancer Center), Dr. Marc Boom (Houston Methodist), and Worthing Jackman (Waste Connections) appear on Glassdoor's new list of the top 100 CEOs for 2021.

Pisters scored particularly well; he ranked third overall on the prestigious list and earned a 99-percent approval rating from MD Anderson employees who shared anonymous feedback on the Glassdoor platform, which publishes reviews and salary information for employers.

Meanwhile, Boom ranked 60 overall with a 93 percent approval, while Jackman came in at 76 overall with a 92 percent approval.

Other Texas executives appearing on the new Glassdoor list are:

  • Seventh-ranked Charles Butt, CEO of San Antonio-based H-E-B (96 percent).
  • Fourth-ranked Gary Kelly, who just announced he's stepping down as CEO of Dallas-based Southwest Airlines (98 percent approval).
  • 55th-ranked Sean Yalamanchi, chairman and president of Richardson-based Infovision (93 percent approval).

"Over the past year, company leaders around the world faced unprecedented challenges to support employees during the COVID-19 crisis. Now, the employees have spoken and it's clear that these CEOs excelled and found new ways to support their people when the world of work flipped upside down," Christian Sutherland-Wong, Glassdoor's CEO, says in a news release.

------

This article originally ran on CultureMap.

Health care leaders joined a virtual panel to discuss the effects of COVID-19 and more. Photo by Dwight C. Andrews/Greater Houston Convention and Visitors Bureau

Overheard: Houston health care experts sound off on how tech and COVID-19 have affected the industry

eavesdropping in houston

There has been an undeniable paradigm shift in the health care industry due to COVID-19 as well as the growth of technology. A group of professionals sat down to discuss what in particular has changed for the industry as a whole as well as at local institutions.

At a panel for Venture Houston, a two-day conference put on by the HX Venture Fund on February 4th and 5th, a few health care professionals weighed in on all the changes to the industry for the startups, investors, corporations, and more who attended the virtual event. Here are some significant overheard moments from the virtual panel — Thinking Past a COVID World.

“For most of health care, this last year has been probably five years of rapid cycle re-innovation and movement forward — particularly in the digital realm.”

Marc Boom, president and CEO of Houston Methodist. From rapid adoption of telemedicine to developing a COVID-19 vaccine in less than a year, health care has seen rapid growth. However, there's fine tuning still needed, Boom continues.

"At the end of the day there's only so much we can do virtually," he adds.

“The most incredible thing was how the vaccines got developed so quickly.”

Chris Rizik, CEO of Renaissance Venture Partners. A large portion of the industry wasn't excited about RNA vaccines, but the COVID-19 vaccines might have changed some minds. It took 11 months to get it out into the world, but 10 of that was purely regulatory, he adds.

"One of the sustaining changes of the COVID-19 pandemic is I think RNA vaccines are here to stay."

​— Paul Klotman, executive dean of Baylor College of Medicine. Klotman adds that the vaccine's trials were so impressively quick because there were just so many COVID patients sick and eligible to enroll.

“I think one of the things the TMC institutions did really well was to decide really early on was to share data.”

Boom says, adding that the TMC represents around 70 percent of Houston's adults and around 90 percent of the city's pediatric patients. This opportunity for data is "one of the most robust sources of real-time data."

"Yes, you're going to compete clinically, but there's a lot of collaboration to be done especially during a pandemic," Boom says of the TMC's member organizations prioritizing collaboration with data sharing.

“Houston has done better than almost all major metropolitan areas because we have came together as a city and a community.”

Klotman says, adding that the vast patient base the TMC is key.

"There's a huge opportunity here for early biotech development," he says. "Because there are so many patients, there are huge opportunities to do new trials."

“The real challenge is for investors to be in tune to know what’s here to stay, and to invest around that."

Rizik says, adding that 2020 was the biggest year for health care investment with more money going into deals, rather than more deals occuring.

“We’re seeing a huge uptick in people interested in health professions, thanks to COVID.”

Boom says of the industry's workforce, which has usually been hard to recruit and grow.

“The medical school communities are all racing to change the way we teach and the kind of information we teach.”

Klotman says of the future of the workforce.

“Unlike most industries, technology is tended to be cumbersome in health care.

​— Boom says adding that new technology means added costs and slowed down processes that can't replace the human touch. Houston Methodist is looking for innovations that don't take health care professionals away from patients.

“If there’s anything this last year has shown us is that as fast as we thought we were going, we need to go faster. We’re excited to work with companies with great ideas.”

— Boom says of the future of tech in health care. "I think we're on a very transformational era in digital health right now — but there's a lot of work to be done still."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Chevron to relocate HQ, executives to Houston

big move

The Energy Capital of the World is adding another jewel to its corporate crown.

With the impending move of Chevron’s headquarters from Northern California to Houston, the Houston area will be home to 24 Fortune 500 companies. Chevron ranks 15th on this year’s Fortune 500.

Oil and gas giant Chevron, currently based in San Ramon, California, will join three Fortune 500 competitors that already maintain headquarters in the Houston area:

  • Spring-based ExxonMobil, No. 7 on the Fortune 500
  • Houston-based Phillips 66, No. 26 on the Fortune 500
  • Houston-based ConocoPhillips, No. 68 on the Fortune 500

Chevron, which posted revenue of $200.9 billion in 2023, employs about 7,000 people in the Houston area and about 2,000 people in San Ramon. The company says its chairman and CEO, Mike Wirth, and vice chairman, Mark Nelson, will move to Houston before the end of 2024.

In an interview with The Wall Street Journal, Wirth acknowledged Chevron’s differences of opinion with California policymakers regarding energy matters.

“We believe California has a number of policies that raise costs, that hurt consumers, that discourage investment and ultimately we think that’s not good for the economy in California and for consumers,” Wirth said.

Chevron expects all of its corporate functions to shift to Houston over the next five years. Jobs that support the company’s California operations will remain in San Ramon, where Chevron employs about 2,000 people. Some Chevron employees in San Ramon will relocate to Houston.

The company’s move to Houston hardly comes as a surprise. Speculation about a relocation to Houston intensified after Chevron sold its 98-acre San Ramon headquarters in 2022 and moved corporate employees to leased office space. Over the past several years, Chevron has shifted various corporate functions to Houston.

“This is just the final step that many industry observers were waiting to happen,” Ken Medlock, senior director of the Baker Institute’s Center for Energy Studies at Rice University, says in a news release.

“To start, Houston provides a world-class location for internationally focused energy companies, which is why there is such a massive international presence here,” Medlock adds. “Texas is also the nation’s largest energy producer across multiple energy sources and is poised to lead in emerging opportunities such as hydrogen and carbon capture, so Houston is a great place for domestically focused activities as well.”

The announcement of Chevron’s exit from California comes just a year after ExxonMobil finalized its relocation from Irving to Spring.

“Chevron’s decision to relocate its headquarters underscores the compelling advantages that position Houston as the prime destination for leading energy companies today and for the future,” Steve Kean, president and CEO of the Greater Houston Partnership, says in a post on the organization’s website.

“With deep roots in our region,” he adds, “Chevron is [a] key player in establishing Houston as a global energy leader. This move will further enhance those efforts.”

------

This article originally ran on EnergyCapital.

Houston climatetech startup raises $21.5M series A to grow robotics solution

seeing green

A Houston energy tech startup has raised a $21.5 million series a round of funding to support the advancement of its automated technology that converts field wastes into stable carbon.

Applied Carbon, previously known as Climate Robotics, announced that its fresh round of funding was led by TO VC, with participation from Congruent Ventures, Grantham Foundation, Microsoft Climate Innovation Fund, S2G Ventures, Overture.vc, Wireframe Ventures, Autodesk Foundation, Anglo American, Susquehanna Foundation, US Endowment for Forestry and Communities, TELUS Pollinator Fund for Good, and Elemental Excelerator.

The series A funding will support the deployment of its biochar machines across Texas, Oklahoma, Arkansas, and Louisiana.

"Multiple independent studies indicate that converting crop waste into biochar has the potential to remove gigatons of CO2 from the atmosphere each year, while creating trillions of dollars in value for the world's farmers," Jason Aramburu, co-founder and CEO of Applied Carbon, says in a news release. "However, there is no commercially available technology to convert these wastes at low cost.

"Applied Carbon's patented in-field biochar production system is the first solution that can convert crop waste into biochar at a scale and a cost that makes sense for broad acre farming," he continues.

Applied Carbon rebranded in June shortly after being named a top 20 finalist in XPRIZE's four-year, $100 million global Carbon Removal Competition. The company also was named a semi-finalist and awarded $50,000 from the Department of Energy's Carbon Dioxide Removal Purchase Pilot Prize program in May.

"Up to one-third of excess CO2 that has accumulated in the atmosphere since the start of human civilization has come from humans disturbing soil through agriculture," Joshua Phitoussi, co-founder and managing partner at TO VC, adds. "To reach our net-zero objectives, we need to put that carbon back where it belongs.

"Biochar is unique in its potential to do so at a permanence and price point that are conducive to mass-scale adoption of carbon dioxide removal solutions, while also leaving farmers and consumers better off thanks to better soil health and nutrition," he continues. "Thanks to its technology and business model, Applied Carbon is the only company that turns that potential into reality."

The company's robotic technology works in field, picking up agricultural crop residue following harvesting and converts it into biochar in a single pass. The benefits included increasing soil health, improving agronomic productivity, and reducing lime and fertilizer requirements, while also providing a carbon removal and storage solution.

"We've been looking at the biochar sector for over a decade and Applied Carbon's in-field proposition is incredibly compelling," adds Joshua Posamentier, co-founder and managing partner of Congruent Ventures. "The two most exciting things about this approach are that it profitably swings the agricultural sector from carbon positive to carbon negative and that it can get to world-scale impact, on a meaningful timeline, while saving farmers money."

------

This article originally ran on EnergyCapital.

Rice University makes top 5 lists of best biz schools in the country

top ranking

MBA programs at Rice University’s Jones Graduate School of Business have landed two top five rankings in The Princeton Review’s annual list of the country’s best business schools.

Rice earned a No. 4 ranking for its online MBA program and a No. 5 ranking for its MBA program in finance.

“These rankings are indicative of the high-quality education offered through all of our MBA programs. Students studying finance at Rice … are taught by faculty whose research and expertise enhances core classes and hard skills, so students are not just prepared to be successful in their careers, but they are also prepared to think critically about their roles and to lead in their industry,” Peter Rodriguez, dean of the Jones Graduate School of Business, says in a news release.

“These rankings are also indicative of our broader approach: offering students flexibility in their pursuit of an MBA, while retaining the experience of studying with world-class faculty — no matter what program they choose,” Rodriguez adds.

Rice also achieved high rankings in two other MBA categories: No. 8 for “greatest resources for women” and No. 10 for “greatest resources for minority students.”

The Princeton Review’s 2024 business school rankings are based on data from surveys of administrators at more than 400 business schools as well as surveys of 32,200 students enrolled in the schools’ MBA programs.

“The schools that made our list for 2024 all have impressive individual distinctions,” Rob Franek, The Princeton Review’s editor-in-chief, says in a news release. “What they share are three characteristics that broadly informed our criteria for these rankings: outstanding academics, robust experiential learning components and excellent career services.”

Rice also ranks as the top school for graduate entrepreneurship programs, which Princeton Review released last fall. The University of Houston ranks as No. 1 for undergraduate entrepreneurship programs.